Metabolic syndrome X Archives - Revista Brasileira de Ginecologia e Obstetrícia
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2012;34(1):4-10
DOI 10.1590/S0100-72032012000100002
PURPOSE: To assess the prevalence of metabolic syndrome and of its defining criteria in women with polycystic ovary syndrome from the Brazilian Southeast, who were stratified according to body mass index and compared to ovulatory controls. METHODS: This was a cross-sectional study conducted on 332 women of reproductive age, who were divided into two groups: Control, consisting of 186 women with regular menstrual cycles and ovulatory symptoms and without a diagnosis of polycystic ovary syndrome or other type of chronic anovulation, and the Polycystic ovary syndrome,Group, consisting of 146 women with a diagnosis of polycystic ovary syndrome (Rotterdam Consensus ASRM/ESHRE). Each group was stratified according to the body mass index, as follows: body mass index ( < 25 ≥25 and <30, and ≥ 30 kg/m²). The frequencies of metabolic syndrome and of its defining criteria and the clinical and hormonal characteristics (follicle stimulating hormone, total testosterone, dehydroepiandrostenedione sulfate) were analyzed. RESULTS: The frequency of metabolic syndrome was six times higher in the obese Polycystic ovary syndrome Group than among control women with the same body mass index (Control with 10.5 versus Polycystic ovary syndrome with 67.9%, p<0.01); twice higher in the Polycystic ovary syndrome Group with body mass index ≥ 25 and <30 kg/m² (Control with 13.2 versus Polycystic ovary syndrome with 22.7%, p<0.01), and three times higher in the Polycystic ovary syndrome Group with body mass index <25 kg/m² (Control with 7.9 versus Polycystic ovary syndrome with 2.5%, p<0.01), compared to control women paired for the same body mass index. Regardless of the body mass index, women with polycystic ovary syndrome had a higher frequency of all the criteria defining metabolic syndrome. CONCLUSION: Women with polycystic ovary syndrome have higher frequency of metabolic syndrome and of its defining criteria regardless of the body mass index. Hyperinsulinemia and hyperandrogenism are important characteristics of the origin of these alterations, especially in obese women with polycystic ovary syndrome.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2012;34(1):4-10
DOI 10.1590/S0100-72032012000100002
PURPOSE: To assess the prevalence of metabolic syndrome and of its defining criteria in women with polycystic ovary syndrome from the Brazilian Southeast, who were stratified according to body mass index and compared to ovulatory controls. METHODS: This was a cross-sectional study conducted on 332 women of reproductive age, who were divided into two groups: Control, consisting of 186 women with regular menstrual cycles and ovulatory symptoms and without a diagnosis of polycystic ovary syndrome or other type of chronic anovulation, and the Polycystic ovary syndrome,Group, consisting of 146 women with a diagnosis of polycystic ovary syndrome (Rotterdam Consensus ASRM/ESHRE). Each group was stratified according to the body mass index, as follows: body mass index ( < 25 ≥25 and <30, and ≥ 30 kg/m²). The frequencies of metabolic syndrome and of its defining criteria and the clinical and hormonal characteristics (follicle stimulating hormone, total testosterone, dehydroepiandrostenedione sulfate) were analyzed. RESULTS: The frequency of metabolic syndrome was six times higher in the obese Polycystic ovary syndrome Group than among control women with the same body mass index (Control with 10.5 versus Polycystic ovary syndrome with 67.9%, p<0.01); twice higher in the Polycystic ovary syndrome Group with body mass index ≥ 25 and <30 kg/m² (Control with 13.2 versus Polycystic ovary syndrome with 22.7%, p<0.01), and three times higher in the Polycystic ovary syndrome Group with body mass index <25 kg/m² (Control with 7.9 versus Polycystic ovary syndrome with 2.5%, p<0.01), compared to control women paired for the same body mass index. Regardless of the body mass index, women with polycystic ovary syndrome had a higher frequency of all the criteria defining metabolic syndrome. CONCLUSION: Women with polycystic ovary syndrome have higher frequency of metabolic syndrome and of its defining criteria regardless of the body mass index. Hyperinsulinemia and hyperandrogenism are important characteristics of the origin of these alterations, especially in obese women with polycystic ovary syndrome.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2007;29(5):241-247
DOI 10.1590/S0100-72032007000500004
PURPOSE: to evaluate the ultra-sensitive C-Reactive Protein level (us-CRP) in patients with Polycystic Ovary Syndrome (PCOS), and the correlation of clinical and laboratory parameters with the us-CRP level. Methods: in this cross-sectional study, 46 women with Polycystic Ovary Syndrome, according to the Rotterdam criteria, and 44 control women have been included. Serum was analyzed for C reactive protein (CRP) levels. Body mass index (BMI), age, circumference waist, HOMA-IR, total, low and high density lipoprotein cholesterol, triglycerides, glucose, testosterone and insulin levels were correlated to CRP level through a linear regression model. RESULTS: PCOS patients not only were older and had higher BMI, but their waist circumference, fasting insulin, HOMA-IR, total and LDL cholesterol were also higher, as compared to the women from the control group. A significant difference was observed in the us-CRP level between the PCOS (2.7 mg/dL±2.17) the control (1.6 mg/dL±1.49) groups. When us-CRP levels were categorized as of low (<1.0 mg/L), moderate (1-3.0 mg/L) and high (3.0 mg/L) risk for cardiovascular episodes, only 28.3% women with PCOS had us-CRP levels defined as low, 34.8% as moderate and 37% as high risk. The prevalence of Metabolic Syndrome was higher in the women with PCOS (30.4%) than in the women from the control group (6.8%). Through a stepwise linear regression model, only waist circumference, presence of metabolic syndrome and age had a confounding effect in the relation between us-CRP and PCOS. After adjustment for confounding factors, PCOS showed an independent effect on us-CRP level. CONCLUSIONS: the us-CRP levels were higher in the PCOS women than in the healthy controls. By a regression model, PCOS showed an independent effect on us-CRP level.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2007;29(5):241-247
DOI 10.1590/S0100-72032007000500004
PURPOSE: to evaluate the ultra-sensitive C-Reactive Protein level (us-CRP) in patients with Polycystic Ovary Syndrome (PCOS), and the correlation of clinical and laboratory parameters with the us-CRP level. Methods: in this cross-sectional study, 46 women with Polycystic Ovary Syndrome, according to the Rotterdam criteria, and 44 control women have been included. Serum was analyzed for C reactive protein (CRP) levels. Body mass index (BMI), age, circumference waist, HOMA-IR, total, low and high density lipoprotein cholesterol, triglycerides, glucose, testosterone and insulin levels were correlated to CRP level through a linear regression model. RESULTS: PCOS patients not only were older and had higher BMI, but their waist circumference, fasting insulin, HOMA-IR, total and LDL cholesterol were also higher, as compared to the women from the control group. A significant difference was observed in the us-CRP level between the PCOS (2.7 mg/dL±2.17) the control (1.6 mg/dL±1.49) groups. When us-CRP levels were categorized as of low (<1.0 mg/L), moderate (1-3.0 mg/L) and high (3.0 mg/L) risk for cardiovascular episodes, only 28.3% women with PCOS had us-CRP levels defined as low, 34.8% as moderate and 37% as high risk. The prevalence of Metabolic Syndrome was higher in the women with PCOS (30.4%) than in the women from the control group (6.8%). Through a stepwise linear regression model, only waist circumference, presence of metabolic syndrome and age had a confounding effect in the relation between us-CRP and PCOS. After adjustment for confounding factors, PCOS showed an independent effect on us-CRP level. CONCLUSIONS: the us-CRP levels were higher in the PCOS women than in the healthy controls. By a regression model, PCOS showed an independent effect on us-CRP level.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2007;29(1):10-17
DOI 10.1590/S0100-72032007000100003
PURPOSE: to evaluate the prevalence of metabolic syndrome in women with polycystic ovary syndrome (PCOS). METHODS: forty six women with PCOS, in accord with Rotterdam criteria (2003), and 44 women with regular menses, without any clinical or laboratorial hyperandrogenism features, and no ultrasonographic ovarian microcysts (control group) were evaluated. For metabolic syndrome, the National Cholesterol Education Program (NCEP, 2002) and the International Diabetes Federation (IDF, 2005) guidelines were considered. RESULTS: the prevalence of metabolic syndrome were 30.4% (NCEP) and 32.6% (IDF) for the women with PCOS, nearly 4-fold higher than that reported for the control group (p<0.004), which were 6.8% (NCEP) and 9.1% (IDF). Women with PCOS had persistently higher prevalence rates of the metabolic syndrome, regardless of matched age and body mass index. The most prevalent factor of the metabolic syndrome among the PCOS subjects was low serum HDL cholesterol which was below 50 mg/dl (52.2%). Waist circumference above 88 cm (47.8%), blood pressure above 130/85 mmHg and fasting glycemia above 110 mg/dl (4.3%) were significantly more frequent among women with PCOS than among control women. CONCLUSIONS: the metabolic syndrome is significantly more frequent in women with PCOS, placing them at higher risk for cardiovascular disease.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2007;29(1):10-17
DOI 10.1590/S0100-72032007000100003
PURPOSE: to evaluate the prevalence of metabolic syndrome in women with polycystic ovary syndrome (PCOS). METHODS: forty six women with PCOS, in accord with Rotterdam criteria (2003), and 44 women with regular menses, without any clinical or laboratorial hyperandrogenism features, and no ultrasonographic ovarian microcysts (control group) were evaluated. For metabolic syndrome, the National Cholesterol Education Program (NCEP, 2002) and the International Diabetes Federation (IDF, 2005) guidelines were considered. RESULTS: the prevalence of metabolic syndrome were 30.4% (NCEP) and 32.6% (IDF) for the women with PCOS, nearly 4-fold higher than that reported for the control group (p<0.004), which were 6.8% (NCEP) and 9.1% (IDF). Women with PCOS had persistently higher prevalence rates of the metabolic syndrome, regardless of matched age and body mass index. The most prevalent factor of the metabolic syndrome among the PCOS subjects was low serum HDL cholesterol which was below 50 mg/dl (52.2%). Waist circumference above 88 cm (47.8%), blood pressure above 130/85 mmHg and fasting glycemia above 110 mg/dl (4.3%) were significantly more frequent among women with PCOS than among control women. CONCLUSIONS: the metabolic syndrome is significantly more frequent in women with PCOS, placing them at higher risk for cardiovascular disease.